Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
STARLITE 2
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
- NCT05239533 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on STARLITE 2 (177Lu-labeled-girentuximab and nivolumab in Clear Cell Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on STARLITE 2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma; Kidney Cancer; Advanced Renal Cell Carcinoma
- Interventions
- 177Lu-labeled-girentuximab; Nivolumab; 89Zr-girentuximab PET/CT; 177Lu whole body (WB) planar and SPECT/CT scans
- Arms
- Safety lead-in Phase: Participants with Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC · Experimental
- Phase 2 Participants · Experimental
- Enrollment
- 9
- Primary outcomes
- Maximal tolerated dose (MTD) of 177Lu-girentuximab
- Overall Response Rate/ORR
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 16, 2022
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05239533 · updated Jan 14, 2026